NO20033261L - Nye blandinger av mikrobielle enzymer - Google Patents

Nye blandinger av mikrobielle enzymer

Info

Publication number
NO20033261L
NO20033261L NO20033261A NO20033261A NO20033261L NO 20033261 L NO20033261 L NO 20033261L NO 20033261 A NO20033261 A NO 20033261A NO 20033261 A NO20033261 A NO 20033261A NO 20033261 L NO20033261 L NO 20033261L
Authority
NO
Norway
Prior art keywords
microbial enzymes
mixtures
new
new mixtures
addition
Prior art date
Application number
NO20033261A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033261D0 (no
Inventor
Manfred Galle
Peter-Colin Gregory
Andreas Potthoff
Friederike Henniges
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10144711A external-priority patent/DE10144711A1/de
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20033261D0 publication Critical patent/NO20033261D0/no
Publication of NO20033261L publication Critical patent/NO20033261L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20033261A 2001-01-19 2003-07-18 Nye blandinger av mikrobielle enzymer NO20033261L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10102495 2001-01-19
DE10144711A DE10144711A1 (de) 2001-01-19 2001-09-11 Neue Gemische mikrobieller Enzyme
PCT/EP2002/000374 WO2002060474A2 (de) 2001-01-19 2002-01-16 Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion

Publications (2)

Publication Number Publication Date
NO20033261D0 NO20033261D0 (no) 2003-07-18
NO20033261L true NO20033261L (no) 2003-07-18

Family

ID=26008287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033261A NO20033261L (no) 2001-01-19 2003-07-18 Nye blandinger av mikrobielle enzymer

Country Status (17)

Country Link
US (1) US20040057944A1 (cs)
EP (1) EP1381386A2 (cs)
JP (1) JP2004524838A (cs)
CN (1) CN1236817C (cs)
AR (1) AR032392A1 (cs)
BR (1) BR0206521A (cs)
CA (1) CA2434808A1 (cs)
CZ (1) CZ20031900A3 (cs)
HU (1) HUP0500560A3 (cs)
IL (1) IL157004A0 (cs)
MX (1) MXPA03005960A (cs)
NO (1) NO20033261L (cs)
NZ (1) NZ527148A (cs)
PL (1) PL362646A1 (cs)
RU (1) RU2003124078A (cs)
SK (1) SK9292003A3 (cs)
WO (1) WO2002060474A2 (cs)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
JP2007509982A (ja) * 2003-10-29 2007-04-19 アルタス ファーマシューティカルズ インコーポレイテッド 血漿コレシストキニン（ｃｃｋ）濃度を制御するための非膵臓プロテアーゼおよび痛みを処置するための非膵臓プロテアーゼ
AU2005227090B2 (en) 2004-03-22 2010-12-09 Abbott Laboratories Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
BRPI0510817A (pt) 2004-05-24 2007-11-20 Novozymes As protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
EP1809320B1 (en) * 2004-10-14 2010-07-21 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
MX2007015471A (es) * 2005-06-24 2008-04-04 Novozymes As Amilasas para uso farmaceutico.
AU2006261443A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Proteases for pharmaceutical use
TW200738256A (en) * 2005-06-24 2007-10-16 Novozymes As Lipases for pharmaceutical use
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
MX2008001557A (es) * 2005-08-15 2008-02-15 Solvay Pharm Gmbh Nucleos de microglobulos de pancreativa adecuados para revestimiento enterico.
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20100196344A1 (en) * 2005-10-14 2010-08-05 Cystic Fibrosis Foundation Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
US7998476B2 (en) 2006-11-22 2011-08-16 Standard Biologics, Inc. Method of treatment using Aspergillus oryzae protease
CA3081308C (en) 2006-12-21 2024-02-20 Novozymes A/S Lipase variants for pharmaceutical use
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
PL2079445T3 (pl) * 2007-02-20 2016-04-29 Allergan Pharmaceuticals Int Ltd Stabilne kompozycje enzymów trawiennych
US20090068174A1 (en) * 2007-09-12 2009-03-12 Kansas University Medical Center Research Institute, Inc. Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2009071550A1 (en) 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
CN101951893A (zh) * 2008-01-03 2011-01-19 雅培产品有限公司 包含纯化的微生物脂肪酶颗粒的药物组合物及其用于预防或治疗消化紊乱的方法
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
WO2010002972A1 (en) * 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2328566A1 (en) * 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
RU2429291C1 (ru) * 2009-12-28 2011-09-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Пищеварительное средство на основе ферментов микробного происхождения
WO2011114224A1 (en) * 2010-03-19 2011-09-22 Axcan Pharma Inc. Gastro-resistant enzyme pharmaceutical compositions
AR093181A1 (es) 2010-10-01 2015-05-27 Aptalis Pharmatech Inc Formulacion con contenido de enzimas digestivas bajo estable
WO2012088303A2 (en) 2010-12-22 2012-06-28 Novozymes North America, Inc. Processes for producing fermentation products
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
RU2016119726A (ru) 2011-08-08 2018-11-02 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
MX348696B (es) * 2011-12-02 2017-06-26 Novozymes As Procesos para la produccion de productos de fermentacion.
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3398594B1 (en) 2012-09-19 2024-07-10 Grespo AB Compositions for improvement of brain function
US20140276632A1 (en) 2013-03-15 2014-09-18 Aptalis Pharma Ltd. Composition containing digestive enzymes and nutrients suitable for enteral administration
CA2915063C (en) 2013-06-24 2023-08-15 Novozymes A/S Process of extracting oil from thin stillage
US11939552B2 (en) 2013-06-24 2024-03-26 Novozymes A/S Process of recovering oil
EP3024479B2 (en) * 2013-07-22 2023-02-08 Allergan Pharmaceuticals International Limited Methods of preparing pancreatin
WO2015069677A1 (en) * 2013-11-05 2015-05-14 Aptalis Pharma Ltd. High potency pancreatin pharmaceutical compositions
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
CA2947998A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
WO2016126970A1 (en) 2015-02-04 2016-08-11 Abbvie Inc. Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US20200291375A1 (en) * 2017-09-24 2020-09-17 Bio-Cat, Inc. Fungal protease mixtures and uses thereof
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
FR3111559A1 (fr) * 2020-06-18 2021-12-24 Azurrx Biopharma, Inc. Formulations non porcines et leurs procédés
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1084431A (en) * 1964-05-06 1967-09-20 Analyses Et De Rech S Biolog M Improvements in and relating to lipases
DE2638088C3 (de) * 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verwendung von SuBmolkenpulver
JP3152958B2 (ja) * 1991-06-14 2001-04-03 天野エンザイム株式会社 微生物起源リパーゼの安定化組成物及び安定化法
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament

Also Published As

Publication number Publication date
CZ20031900A3 (cs) 2003-10-15
CA2434808A1 (en) 2002-08-08
NO20033261D0 (no) 2003-07-18
WO2002060474A3 (de) 2003-10-30
CN1487837A (zh) 2004-04-07
HUP0500560A3 (en) 2006-06-28
HUP0500560A2 (hu) 2005-09-28
IL157004A0 (en) 2004-02-08
BR0206521A (pt) 2004-02-17
JP2004524838A (ja) 2004-08-19
SK9292003A3 (en) 2003-12-02
RU2003124078A (ru) 2005-01-27
EP1381386A2 (de) 2004-01-21
AR032392A1 (es) 2003-11-05
PL362646A1 (en) 2004-11-02
WO2002060474A2 (de) 2002-08-08
MXPA03005960A (es) 2003-09-05
US20040057944A1 (en) 2004-03-25
NZ527148A (en) 2005-01-28
CN1236817C (zh) 2006-01-18

Similar Documents

Publication Publication Date Title
NO20033261L (no) Nye blandinger av mikrobielle enzymer
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
PT1729797E (pt) Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
NZ606504A (en) Modified proteases that inhibit complement activation
WO2008021987A3 (en) Proteolytic enzyme formulations
DK39093D0 (da) Enzym
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
NO20080438L (no) Proteaser til farmasoytisk anvendelse
BR9908280A (pt) Inibidores de enzimas de fosfolipase
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
NO20100214L (no) Preparat for a redusere LIPG ekspresjon hos en pasient og anvendelsen av dette
WO2007053619A3 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
DK0401508T3 (da) Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
WO2003061718A3 (en) Medical articles having enzymatic surfaces for localized therapy
MX2024011115A (es) Enzimas escualeno-hopeno-ciclasa (shc) y variantes de enzimas.
DK1330262T3 (da) Anvendelse af enzymer udvundet fra ciliater som lægemidler til fremme af fordöjelsen
WO2005007663A3 (en) Fluorogenic enzyme substrates and uses thereof
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
ES2059666T3 (es) Utilizacion de enzimas catabolicas para el tratamiento de una infeccion vih.
Choi et al. Multiple-layer substrate zymography for detection of several enzymes in a single sodium dodecyl sulfate gel
SI1539815T1 (sl) Kristalna struktura encima, ki pretvarja angiotenzin (ACE), in njegove uporabe
RU2002120776A (ru) Способ профилактики рецидивов гнойного дакриоцистита после дакриоцисториностомии
DE602004023796D1 (de) Stabilisierungsmittel für Enzyme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application